29th Jun 2005 07:01
Sinclair Pharma PLC29 June 2005 SINCLAIR PHARMA PLC Decapinol(R) licensing deal in Israel Three new licensing agreements in North America and three in Columbia XclairTM, SalinumTM and SSTTM Godalming UK, 29 June, 2005: Sinclair Pharma plc ("Sinclair" or the "Company")(SPH.L), the specialty pharmaceutical company, today announces a new licensingagreement for Decapinol(R), the company's oral rinse for the treatment andprevention of gingivitis, which is currently approved in the EU and whichrecently received US FDA approval. Sinclair also announces the signing of afurther three licensing agreements in North America (US and Canada) and three inColumbia. Under the terms of the Decapinol(R) agreement, the product has been exclusivelylicensed for ten years to Kivema Ltd. ("Kivema") for distribution in Israel.Kivema specialises in oral care, dermatology and ophthalmology and has fullcoverage of the retail Pharma trade across Israel as well as direct access toover 1000 dental clinics. Sinclair are pleased to announce that they have appointed Align Pharmaceuticalsas licensees in North America (US and Canada) on ten year exclusive contractsfor the three products below. Align is a new US company with strong venturecapital funding, specialised in radiation oncology, dental and rheumatologyproducts. The company will target the US market via a combination of contractsalespeople and co-promotion partners who will have over 100 salesrepresentatives selling the following products. In addition Sinclair announce that the same three products have been licensedexclusively in Columbia to Bio Pharma, a company representing major pharmacompanies such as Abbott, Novartis and Zambon. The products licensed to Align and Bio Pharma are: XclairTM for the treatment of radiation dermatitis; SalinumTM SalinumTM is Sinclair's saliva replacement product for the treatment of drymouth syndrome, ("xerostomia") where the salivary glands are able to producelittle or no saliva. SSTTM SSTTM is Sinclair's saliva stimulating tablet for the treatment of milder formsof dry mouth syndrome. Dr Michael Flynn, CEO of Sinclair, said: "The licensing deal in Israel is afurther advancement of our international commercialisation strategy forDecapinol(R). We believe that a good efficacy profile and high level of patientacceptance of Decapinol(R) provides very significant patient benefits and expectthe product to rapidly gain market acceptance with each new territory launch. We are also very pleased to have signed up Align and Bio Pharma as licensees forXclairTM, SalinumTM and SSTTM. In so doing we are following our strategy oflicensing our products to distributors whom we believe will best promote ourproducts in their territories." Enquiries: Sinclair Pharma plcDr Michael Flynn, CEO Tel: 01483 426 6444John Barrington-Carver (Corporate PR) Tel: 07831 655 630 Financial DynamicsLucy Briggs Tel: 0207 831 3113 www.sinclairpharma.com Notes to editors: Sinclair Pharma plc Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health, oncology support and dermatology, and bringing them tothe international market place via out-licensing partners. The Company combinesproduct evaluation, product development, regulatory and business developmentexpertise to add value to its acquired and in-house developed products. A keyelement of the Sinclair business model is to minimise risk and exposure byavoiding involvement in lengthy R&D programmes and rapidly achieving globaldistribution through a network of marketing partners. The Company has alreadylicensed its products for distribution in over 40 countries around the world. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma